A Study of YM155 Plus Docetaxel in Subjects With Stage III (Unresectable) or Stage IV Melanoma

NCT01009775 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: YM155
DRUG: Docetaxel

Sponsor

Astellas Pharma Inc